Industrial biotransformations in the synthesis of building blocks leading to enantiopure drugs.
Due to the growing demand of enantiomerically pure compounds, as well as the increasing strict safety, quality and environmentally requirements of industrial synthetic processes, the development of more sustainable, healthy and economically attractive strategies for the synthesis of chiral biologically active molecules is still an open challenge in the pharmaceutical industry. In this context, the biotransformations field has emerged as a real alternative to traditional synthetic routes, because of the exquisite chemo-, regio- and enantioselectivities commonly displayed by enzymes; thus, biocatalysis is becoming a widespread methodology for the synthesis of chiral compounds, not only at laboratory scale, but also at industrial scale. As hydrolases and oxido-reductases are the most employed enzymes, this review is focused on describing several industrial processes based on the use of these enzymes for obtaining chiral compounds useful for the pharmaceutical industry.
Department of Organic and Pharmaceutical Chemistry, Faculty of Pharmacy, Complutense University, Madrid, Spain.
D
D
Muñoz Solano
P
P
Hoyos
M J
MJ
Hernáiz
A R
AR
Alcántara
J M
JM
Sánchez-Montero
D001711:Biotransformation; D004345:Drug Industry / Q000379:methods*; D006867:Hydrolases / Q000378:metabolism; D010084:Oxidation-Reduction; D004364:Pharmaceutical Preparations / Q000138:chemical synthesis* / Q000737:chemistry*; D013237:Stereoisomerism
D004364:Pharmaceutical Preparations; D006867:Hydrolases